KKR & Co. is creating a firm that will invest in diagnostic technologies such as Covid-19 tests, adding to its bets on fast-growing health-care companies. The new entity, Sapphiros, will be led by industry veteran Namal Nawana, KKR said Wednesday in a statement seen by Bloomberg. Nawana previously was chief executive officer of medical-device maker Smith & Nephew Plc and Alere Inc., a test provider that Abbott Laboratories acquired in 2017.
KKR has wagered on growth-stage companies in the sector through a strategy run by partner Ali Satvat, who’s also co-head of the health-care industry team within the firm’s Americas private equity platform. Recent bets include starting mental-heath services provider Geode Health, medical-device platform Zeus Health, and Falcon Vision, which focuses on emerging ophthalmology assets.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.